Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4.6% – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP) shares were down 4.6% on Thursday . The company traded as low as $17.80 and last traded at $17.97. Approximately 51,620 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 152,526 shares. The stock had previously closed at $18.83.

Rapport Therapeutics Trading Down 1.8 %

The company’s fifty day moving average is $23.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Values First Advisors Inc. bought a new stake in Rapport Therapeutics in the 3rd quarter valued at approximately $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Rapport Therapeutics in the third quarter valued at approximately $34,000. SG Americas Securities LLC bought a new stake in shares of Rapport Therapeutics in the third quarter worth $101,000. Sandia Investment Management LP acquired a new position in Rapport Therapeutics during the second quarter worth $116,000. Finally, MetLife Investment Management LLC acquired a new stake in Rapport Therapeutics in the 3rd quarter valued at $117,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.